LYCOS RETRIEVER 
Pharmaceuticals
built 132 days ago
Manhattan Pharmaceuticals will hold a management discussion call and webcast to describe the OE results in further detail, and to discuss the advancement of its four clinical stage product candidates at 8:30 AM ET on Tuesday, July 10, 2007. To access the call, please dial 800.289.0468 (domestic) or 913.981.5517 (international) five minutes prior to the start time. A replay of the call will be available approximately 2 hours following the event and will last until Friday, July 13, 2007 at 6:00 PM ET. To access a replay, please dial 888.203.1112 (domestic) or 719.457.0820 (international), and provide the pass code 1451123. To access the live audio webcast please visit the "Investors & Media" section of the company's website located at http://www.manhattanpharma.com. An archived webcast will be available on the website approximately 2 hours after the event and will be available in the archive until Friday, July 13, 2007 at 6:00 PM ET.
Source:
GAITHERSBURG, MD, June 1, 2004 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it has successfully completed a single, escalating dose Phase 1 clinical trial of the first-in-class HIV Maturation Inhibitor, PA-457. Following oral administration to uninfected, healthy volunteers, PA-457 was well tolerated and exhibited favorable oral bioavailability and pharmacokinetics. A detailed update on PA-457 will be made in July at the XV International AIDS Conference in Bangkok, Thailand.
Source:
Next Pharmaceuticals was founded in 1997 with the purpose of developing new, patented, natural ingredients for healthy living products for the dietary supplement, food, and beverage industries. The goal of the company is to expand self-care and promote proactive, preventative healthcare. Next Pharmaceuticals has successfully developed six patented plants extracts, both patented and proprietary, that have significantly expanded the choices for self-care products while providing consumer brands with powerful product differentiation. In addition to the botanical products, Next has acquired the patent to one of the safest and most absorbable mineral compounds essential for good health.
Source:
Panacos Pharmaceuticals is engaged in the discovery and development of small molecule, orally available drugs for the treatment of HIV and other major human viral diseases. The Company's proprietary discovery technologies focus on novel targets in the virus life cycle, including virus fusion and virus maturation, the first and last steps of viral infection.
Source:
"The American Stock Exchange gladly welcomes Javelin Pharmaceuticals, Inc. to our market," said John McGonegal, Senior Vice President of Amex's Equities Group. "Javelin Pharmaceuticals performs important work in its industry, and we hope to be supportive of Javelin's endeavors as it seeks to expand and deliver its services to a demanding marketplace."
Source:
Interested parties may access a live webcast of the presentation and accompanying slides by visiting the Investor Relations section of Memory Pharmaceuticals' website at http://www.memorypharma.com. An archived version of the webcast will be available at the same location through April 28, 2006.
Source:
MORE ABOUT
Pharmaceuticals